Pharma Focus Asia

BiomeBank Plans to Open a New State-of-the-Art GMP Facility in Adelaide, Australia


BiomeBank plans to open a new good manufacturing practise (GMP) facility to advance biomedical research and production in Adelaide, Australia.


The opening of its new GMP manufacturing facility marks a pivotal moment in bolstering the worldwide availability of their established donor-derived microbiome-based therapy. Moreover, this expansion is strategically aligned to propel the continued development and enhancement of their next-generation therapies.

The new facility in Adelaide's biomedical area is set up to help people work together and come up with new ideas in South Australia's growing medical field. Alongside the GMP facility for production, it will also include a brand-new research and development lab and office space.

The facility will aid in expanding the distribution of microbiome-based therapies to additional regions to address the increasing worldwide need. Additionally, the research and development lab will play a pivotal role in advancing pipeline of second-generation products.

This facility will enable the continued development and expansion of consortiome TM—a groundbreaking artificial cultured human microbiome produced within a bioreactor. This innovative technology holds promise in offering widespread replacement of human gut microbes at a scalable level, potentially addressing various common diseases.

The upcoming facility will increase its current staff from 18 to 32, and expect ongoing expansion throughout the year 2024.


Name    BiomeBank
Type      New Construction

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference